licensing agreement

The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.

Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.

The deal will accelerate delivery of high-quality, deidentified clinical databases to CancerLinQ, its oncologist subscribers, partners, and the broader cancer community.